🇺🇸 FDA
Patent

US 6503939

Combination regimens using 3,3-substituted indoline derivatives

expired A61KA61K31/57A61K45/06

Quick answer

US patent 6503939 (Combination regimens using 3,3-substituted indoline derivatives) held by Ligand Pharmaceuticals Incorporated expires Mon Jan 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Ligand Pharmaceuticals Incorporated
Grant date
Tue Jan 07 2003 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/57, A61K45/06, A61P, A61P15/18